https://www.selleckchem.com/products/vx-11e.html
Background Immune checkpoint blockade therapies including cytotoxic-T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1) inhibitors have become indispensable tools for treating melanoma and other cancers. An increasing number of diverse cutaneous adverse reactions to immunotherapy have been documented in the literature and have been reported to affect up to 40% of patients treated with targeted therapies. Method results Herein, we report a case of a patient with metastatic melanoma treated with checkpoint inhi
Like
Comment
Share
